Dr Reddy’s Subsidiary, Opens a 70,000 sq. ft. Biologics Facility in Hyderabad’s Genome Valley

On June 3, 2024, Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited subsidiary, inaugurated a 70,000 sq. ft. biologics facility in Genome Valley, Hyderabad, India. The facility will support customers with the process, analytical development, and small-scale manufacturing of antibodies and other recombinant proteins for preclinical and early-phase clinical trials. While the process and analytical development laboratories are already operational, the manufacturing capacity is set to be commissioned later in 2024.

The state-of-the-art facility features top-tier equipment and control systems and is staffed by an experienced team to ensure smooth transitions to large-scale commercial CGMP manufacturing. This facility complements Aurigene’s existing discovery capabilities and infrastructure, focusing on recombinant proteins such as mAbs, bi- and multi-specifics, immune-fusion molecules, antibody-drug conjugates, and other complex proteins.

Aurigene now offers a comprehensive end-to-end service from discovery to large-scale commercial manufacturing across three proximate campuses, ensuring efficient delivery from “concept to commercial.” The new Genome Valley facility will provide robust, compliant, and cost-effective cell lines, process development solutions, and analytical methods, supporting customers in swiftly advancing through clinical development.

This facility opening is part of several strategic initiatives by Aurigene to foster rapid growth in both small molecule and biologics sectors. Recent initiatives include AI/ML-led drug discovery in small molecules and a collaboration with Vipergen, a provider of DNA-encoded library (DEL) technologies.

The CEO of Aurigene, Akhil Ravi, said, “The journey started a year back when we decided to invest in creating the facility. It is great to see the facility operational. The addition of this capacity and capabilities shows our firm commitment to expanding our biologics business, building on 25 years of proven experience. The state-of-the-art facility will enable us to service our global customers efficiently and support the development of innovative medicine.”

About Dr. Reddy’s

Dr Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. Founded in 1984, it provides access to affordable and innovative medicines under the ‘Good Health Can’t Wait’ guiding principle. Its product and service portfolio includes APIs, generics, branded generics, biosimilars, and OTC products.

On June 4, 2024, the share price of Dr Reddy opened at ₹5,807.00, touching the day’s high of ₹5,810.30 as of 09:40 PM on the NSE

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.